Shots:
- Regeneron reported 3yr. data from an extension study of P-III (PULSAR) trial of Eylea for wAMD pts, randomized to Eylea HD (8mg; Q3M or Q4M) or Eylea (2mg; Q2M)
- After 2yrs., 88% of Eylea HD patients maintained a dosing interval of ≥3 months, while in 60wk. extension, 77%, 58%, 40% & 24% (out of 375 pts) had a dosing interval of ≥3, ≥4, ≥5, & ≥6mos., respectively. Vision gains & reduced retinal thickness were sustained during 3yr.
- Pts who received Eylea (Q2M for 96wks.) switched to Eylea HD (Q3M) in the extension, where 79%, 43% & 16% (out of 186 pts) maintained a ≥3, ≥4 & ≥5mos. dosing interval, respectively, with sustained vision & anatomical improvements. Data was presented at Angiogenesis 2025
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Reports Interim Data from P-III (C-POST) Trial of Libtayo Adjuvant to Treat High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
